Erasca, Inc. (ERAS) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 3, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 11, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ERAS SEC filings page.
This page shows Erasca, Inc. (ERAS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Erasca remains a research-funded business: 2025 losses largely became cash use, while low leverage keeps financing separate from operations.
In FY2025, the net loss of$124.5M nearly matched operating cash flow of-$95.5M . That near-match, alongside free cash flow of-$95.6M on only$128K of capital spending, shows the cash requirement is primarily the research program rather than a large asset-building footprint.
The cost base is science-heavy: R&D was
FY2025’s 0.2x debt-to-equity and 10.0x current ratio indicate modest leverage and substantial reported current-asset coverage. Financing supplied
Financial Health Signals
Erasca, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Erasca, Inc. passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
Erasca, Inc. reported a net loss of $124.5M while operations used $95.5M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Erasca, Inc.'s EBITDA was -$46.9M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 25.6% from the same quarter a year earlier. Against the prior quarter it is up 74.9%.
Erasca, Inc. reported -$44.1M in net income in Q2 2026. This represents a decrease of 30.1% from the same quarter a year earlier. Against the prior quarter it is up 76.0%.
Erasca, Inc. earned -$0.14 per diluted share (EPS) in Q2 2026. This represents a decrease of 16.7% from the same quarter a year earlier. Against the prior quarter it is up 76.7%.
Not reported for Q2 2026.
Cash & Balance Sheet
Erasca, Inc. recorded an outflow of $27.3M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 32.7% from the same quarter a year earlier. Against the prior quarter it is up 0.5%.
Erasca, Inc. held $42.5M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
Erasca, Inc.'s ROE was -12.2% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 3.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 34.4 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
Erasca, Inc. invested $35.9M in research and development in Q2 2026. This represents an increase of 69.6% from the same quarter a year earlier. Against the prior quarter it is up 31.7%.
Erasca, Inc. invested $8K in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 73.3% from the same quarter a year earlier. Against the prior quarter it is down 77.8%.
Not reported for Q2 2026.
ERAS Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $35.9M+69.6% | $27.3M+5.0% | N/A | $22.5M-18.7% | $21.2M-35.9% | $26.0M-9.1% | N/A | $27.6M+9.6% |
| SG&A Expenses | $11.7M+23.9% | $10.6M+10.2% | N/A | $10.1M+4.8% | $9.5M-22.8% | $9.7M-6.0% | N/A | $9.6M+1.8% |
| Operating Income | -$47.6M-24.9% | -$187.9M-427.4% | N/A | -$34.5M+7.2% | -$38.1M+43.8% | -$35.6M+8.3% | N/A | -$37.2M-7.5% |
| EBITDA | -$46.9M-25.6% | -$187.2M-437.8% | N/A | -$33.8M+7.2% | -$37.3M+44.0% | -$34.8M+8.0% | N/A | -$36.4M-8.0% |
| Net Income | -$44.1M-30.1% | -$183.4M-492.4% | N/A | -$30.6M+1.9% | -$33.9M+46.4% | -$31.0M+11.6% | N/A | -$31.2M-2.8% |
| EPS (Basic) | -$0.14-16.7% | -$0.60-445.5% | -$0.10-11.1% | -$0.110.0% | -$0.12+58.6% | -$0.11+52.2% | -$0.09+52.6% | -$0.11+45.0% |
| EPS (Diluted) | -$0.14-16.7% | -$0.60-445.5% | -$0.10-11.1% | -$0.110.0% | -$0.12+58.6% | -$0.11 | -$0.09 | -$0.11 |
| Diluted Shares (Avg) | 311M+9.9% | 304M+7.4% | N/A | 284M+0.5% | 283M+30.1% | 283M | N/A | 282M |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense, Income Tax.
ERAS Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $435.1M-2.3% | $461.2M-2.1% | $396.2M-21.2% | $420.4M-20.5% | $445.4M-15.3% | $471.2M+27.4% | $502.5M+27.1% | $528.9M+26.1% |
| Current Assets | $278.4M-10.4% | $253.8M-19.3% | $286.2M-7.3% | $299.9M-9.2% | $310.7M-25.7% | $314.6M+2.6% | $308.8M-3.7% | $330.2M+7.9% |
| Cash & Equivalents | $42.5M-35.7% | $47.3M-33.0% | $73.8M+9.0% | $70.2M+2.0% | $66.1M-61.7% | $70.5M-59.2% | $67.7M-27.2% | $68.9M-39.0% |
| Short-Term Investments | $226.2M-3.5% | $196.5M-16.0% | $202.3M-12.3% | $218.2M-12.7% | $234.5M-0.5% | $234.1M+5.9% | $230.6M+5.2% | $250.0M+36.0% |
| Long-Term Investments | $115.5M+34.2% | $164.7M+54.7% | $65.7M-53.8% | $74.0M-48.8% | $86.1M+66.1% | $106.5M | $142.2M+1374.4% | $144.4M+207.9% |
| Total Liabilities | $73.2M+0.1% | $67.7M-5.6% | $71.0M-10.2% | $72.5M-8.0% | $73.1M-2.0% | $71.7M-12.1% | $79.0M+0.5% | $78.9M-2.0% |
| Current Liabilities | $33.6M+19.3% | $26.7M+4.7% | $28.5M-9.2% | $28.7M-4.4% | $28.2M+13.1% | $25.5M-15.8% | $31.4M+20.0% | $30.0M+12.3% |
| Non-Current Liabilities | $39.6M-11.9% | $41.0M-11.3% | $42.5M-10.8% | $43.8M-10.3% | $45.0M-9.6% | $46.3M-9.9% | $47.6M-9.2% | $48.8M-9.1% |
| Total Equity | $361.9M-2.8% | $393.5M-1.5% | $325.2M-23.2% | $347.9M-22.7% | $372.3M-17.5% | $399.5M+38.5% | $423.5M+33.7% | $450.0M+32.8% |
| Retained Earnings | -$1.1B-34.5% | -$1.1B-34.7% | -$892.2M-16.2% | -$863.1M-17.4% | -$832.5M-18.2% | -$798.6M-24.6% | -$767.7M-26.7% | -$735.4M-27.6% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
ERAS Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$27.3M-32.8% | -$27.4M+13.2% | -$21.7M+11.6% | -$21.7M+3.4% | -$20.5M+29.6% | -$31.6M+5.1% | -$24.6M+0.9% | -$22.4M+7.1% |
| Depreciation & Amortization | $716K-9.0% | $723K-12.0% | $743K-10.7% | $755K-10.3% | $787K-28.5% | $822K-17.6% | $832K-11.7% | $842K-10.5% |
| Stock-Based Compensation | $9.6M+50.1% | $8.5M+26.0% | N/A | $6.0M-10.1% | $6.4M-10.9% | $6.7M-2.0% | N/A | $6.6M+6.4% |
| Capital Expenditures | $8K-73.3% | $36K-56.6% | $9K | $6K+20.0% | $30K+130.8% | $83K+97.6% | $0-100.0% | $5K-97.9% |
| Free Cash Flow | -$27.3M-32.7% | -$27.4M+13.3% | -$21.7M+11.6% | -$21.7M+3.4% | -$20.6M+29.6% | -$31.6M+5.0% | -$24.6M+1.2% | -$22.4M+7.9% |
| Investing Cash Flow | $19.5M+23.8% | -$243.8M-811.6% | $24.7M+9.3% | $25.7M+125.1% | $15.7M+118.2% | $34.3M+243.6% | $22.6M+397.6% | -$102.6M-5562.0% |
| Financing Cash Flow | $3.1M+585.5% | $244.7M+741306.1% | $575K-28.2% | $41K-99.8% | $447K-99.8% | $33K-99.5% | $801K+75.7% | $21.1M+301285.7% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
ERAS Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -12.2%-3.1pp | -46.6%-38.9pp | N/A | -8.8%-1.9pp | -9.1%+4.9pp | -7.8%+4.4pp | N/A | -6.9%+2.0pp |
| Return on Assets | -10.1%-2.5pp | -39.8%-33.2pp | N/A | -7.3%-1.4pp | -7.6%+4.4pp | -6.6%+2.9pp | N/A | -5.9%+1.3pp |
| Current Ratio | 8.29-2.7x | 9.52-2.8x | 10.04+0.2x | 10.45-0.6x | 11.04-5.8x | 12.35+2.2x | 9.84-2.4x | 11.00-0.4x |
| Debt-to-Equity | 0.200.0x | 0.170.0x | 0.220.0x | 0.210.0x | 0.200.0x | 0.18-0.1x | 0.19-0.1x | 0.18-0.1x |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Erasca, Inc. ERAS | FY2025 | N/A | -$124.5M | N/A | $5.2B | — |
| Olema Pharmaceuticals, Inc. OLMA | FY2025 | N/A | -$162.5M | N/A | $719.7M | — |
| Prothena Corporation plc PRTA | FY2025 | $9.7M | -$244.1M | N/A | $429.2M | 55/100 |
| Alumis Inc. ALMS | FY2025 | $24.1M | -$243.3M | N/A | $886.6M | 37/100 |
| iTeos Therapeutics, Inc. ITOS | FY2024 | $35.0M | -$134.4M | N/A | $448.7M | 33/100 |
| Zevra Therapeutics, Inc. ZVRA | FY2025 | $106.5M | $83.2M | 78.2% | $593.2M | 52/100 |
Where Erasca, Inc. Ranks
Frequently Asked Questions
Is Erasca, Inc. profitable?
No, Erasca, Inc. (ERAS) reported a net income of -$124.5M in fiscal year 2025.
What is Erasca, Inc.'s EBITDA?
Erasca, Inc. (ERAS) had EBITDA of -$137.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Erasca, Inc.'s return on equity (ROE)?
Erasca, Inc. (ERAS) has a return on equity of -38.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Erasca, Inc.'s free cash flow?
Erasca, Inc. (ERAS) recorded an outflow of $95.6M in free cash flow during fiscal year 2025. This represents a 12.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Erasca, Inc.'s operating cash flow?
Erasca, Inc. (ERAS) recorded an outflow of $95.5M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Erasca, Inc.'s total assets?
Erasca, Inc. (ERAS) had $396.2M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Erasca, Inc.'s capital expenditures?
Erasca, Inc. (ERAS) invested $128K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Erasca, Inc. spend on research and development?
Erasca, Inc. (ERAS) invested $92.9M in research and development during fiscal year 2025.
What is Erasca, Inc.'s current ratio?
Erasca, Inc. (ERAS) had a current ratio of 10.04 as of fiscal year 2025, which is generally considered healthy.
What is Erasca, Inc.'s debt-to-equity ratio?
Erasca, Inc. (ERAS) had a debt-to-equity ratio of 0.22 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Erasca, Inc.'s return on assets (ROA)?
Erasca, Inc. (ERAS) had a return on assets of -31.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Erasca, Inc.'s P/E ratio?
Erasca, Inc. (ERAS) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $5.2B as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Erasca, Inc.'s price-to-sales ratio?
Erasca, Inc. (ERAS) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $5.2B as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Erasca, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Erasca, Inc. (ERAS) held $341.8M in cash, cash equivalents and investments, and reported an operating cash outflow of $95.5M over that year. Dividing the one by the other, the reported balance equals about 43 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Erasca, Inc.'s Piotroski F-Score?
Erasca, Inc. (ERAS) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Erasca, Inc.'s earnings high quality?
Erasca, Inc. (ERAS) reported a net loss of $124.5M while operations used $95.5M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.